On Jan. 26, the FDA revoked its emergency use authorization for Evusheld, a monoclonal antibody authorized to treat COVID-19, after finding it’s ineffective against about 90 percent of circulating variants.
Read the full post on Becker's Hospital Review - Healthcare News
